Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

Jill A. Bell (), Aaron Galaznik, Marlo Blazer, Huai-Che Shih, Eileen Farrelly, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram and Douglas V. Faller
Additional contact information
Jill A. Bell: Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals International Co.
Aaron Galaznik: Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals International Co.
Marlo Blazer: Xcenda LLC
Huai-Che Shih: Xcenda LLC
Eileen Farrelly: Xcenda LLC
Augustina Ogbonnaya: Xcenda LLC
Michael Eaddy: Xcenda LLC
Robert J. Fram: Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals International Co.
Douglas V. Faller: Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals International Co.

PharmacoEconomics - Open, 2019, vol. 3, issue 2, No 12, 237-245

Abstract: Abstract Background and Objective Significant clinical burden is associated with higher-risk myelodysplastic syndromes (HR-MDS); however, the economic burden has not been fully examined. We examined cost of care and healthcare utilization (HCU) in HR-MDS patients engaged in routine care in the United States (US). Methods Adult US patients diagnosed with HR-MDS from 1/1/2008 to 10/31/2015 were identified from the Optum database. Patients were followed until death, progression to acute myeloid leukemia (AML), end of enrollment, or end of study (12/31/2015). Myelodysplastic syndrome (MDS)-related costs/HCU (including medical/pharmacy claims with a primary diagnosis of MDS, MDS-related treatment, or supportive care) and non-MDS-related costs/HCU were evaluated. Costs were calculated as per-patient per-month (PPPM) costs adjusted to 2015 US dollars. Results Of the 209 HR-MDS patients included, median follow-up was 9.9 months (interquartile range 4.6–17.9), and 69.4% had at least one inpatient admission, 56.9% had at least one emergency department visit, and nearly all patients had at least one outpatient visit. Average PPPM costs over follow-up were $17,361; year 1 versus year 2 costs were higher ($17,337 vs $12,976) following HR-MDS diagnosis. The majority of costs were for MDS-related medical services ($10,327 PPPM). MDS-related medical PPPM costs decreased from $10,557 (year 1) to $6530 (year 2). The main drivers of MDS-related medical costs and the decrease in year 2 were chemotherapy and supportive care costs. Conclusions The economic burden of HR-MDS is considerable, particularly within the first year of diagnosis. Treatment/supportive care costs accounted for a significant portion of MDS-related costs. As HR-MDS treatment evolves, the economic impact and HCU need to be further investigated.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-018-0100-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:2:d:10.1007_s41669-018-0100-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-018-0100-5

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().